Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

A method of inhibiting PDE2 in a mammal comprising administering to the mammal an effective amount of a compound of formula (I)

• wherein
• A is selected from the group Aa consisting of
• wherein above mentioned groups are substituted with one R5 and one R6;
• R1 is selected from the group R1a consisting of
• halogen, C1-3-alkyl- and C3-6-cycloalkyl- wherein the above mentioned C1-3-alkyl-, and C3-6-cycloalkyl- groups may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, NC— and HO—;
• R2 is selected from the group R2a consisting of
• aryl and heteroaryl,
• wherein the above mentioned aryl and heteroaryl-groups may optionally be substituted with 1 to 5 substituents R4;
• R3 is selected from the group R3a consisting of
• H— and C1-3-alkyl-,
• wherein the above mentioned C1-3-alkyl-groups may optionally be substituted with 1 to 7 substituents independently from each other selected from the group consisting of halogen;
• R4 is independently from each other selected from the group R4a consisting of
• halogen, NC—, HO—, C1-4-alkyl- and C1-3-alkyl-O—
• wherein the above mentioned C1-4-alkyl- and C1-3-alkyl-O-groups may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO— and F—;
• R5 is selected from the group R5a consisting of
• H—, halogen, NC—, HO— and C1-3-alkyl-,
• wherein the above mentioned C1-3-alkyl-group may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO— and F—
• or R5 and R6 together form an group O═;
• R6 is selected from the group R6a consisting of
• H—, halogen, NC—, HO— and C1-3-alkyl-,
• wherein the above mentioned C1-3-alkyl-group may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO— and F—
• or R5 and R6 together form a group O═;
• or a pharmaceutically acceptable salt thereof.